10. REFERENCES

1.Gontero, P., et al., EAU Guidelines on Non-muscle-invasive Bladder Cancer (T1, T1 and CIS), in EAU Guidelines, Edn. presented at the 41st EAU Annual Congress London. 2026, EAU Guidelines Office
https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer

2.van der Heijden, A.G., et al., EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer in EAU Guidelines, Edn. presentat at the 41st EAU Annual Congress London. 2026, EAU Guidelines Office
https://uroweb.org/guidelines/muscle-invasive-and-metastatic-bladder-cancer

3.Neuzillet, Y., et al., EAU Guidelines on Primary Urethral Carcinoma, in EAU Guidelines, Edn. presented at the 41st EAU Annual Congress London. 2026, EAU Guidelines Office
https://uroweb.org/guidelines/primary-urethral-carcinoma

4.Masson-Lecomte, A., et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: Summary of the 2025 Update. Eur Urol, 2025. 87: 697.
https://www.ncbi.nlm.nih.gov/pubmed/40118741

5.Bob Phillips, C.B., Dave Sackett, Doug Badenoch, Sharon Straus, Brian Haynes, Martin Dawes since November 1998. Updated by Jeremy Howick March 2009. Oxford Centre for Evidence-based Medicine Levels of Evidence (May 2009. 2009.
https://www.cebm.ox.ac.uk/resources/levels-of-evidence/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009

6.Guyatt, G.H., et al. Going from evidence to recommendations. BMJ, 2008. 336: 1049.
https://www.ncbi.nlm.nih.gov/pubmed/18467413

7.Siegel, R.L., et al. Cancer statistics, 2023. CA Cancer J Clin, 2023. 73: 17.
https://www.ncbi.nlm.nih.gov/pubmed/36633525

8.Soria, F., et al. Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World J Urol, 2017. 35: 379.
https://www.ncbi.nlm.nih.gov/pubmed/27604375

9.Almas, B., et al. Higher than expected and significantly increasing incidence of upper tract urothelial carcinoma. A population based study. World J Urol, 2021. 39: 3385.
https://www.ncbi.nlm.nih.gov/pubmed/33420812

10.Shariat, S.F., et al. Gender differences in radical nephroureterectomy for upper tract urothelial carcinoma. World J Urol, 2011. 29: 481.
https://www.ncbi.nlm.nih.gov/pubmed/20886219

11.Baard, J., et al. Contemporary patterns of presentation, diagnostics and management of upper tract urothelial cancer in 101 centres: the Clinical Research Office of the Endourological Society Global upper tract urothelial carcinoma registry. Curr Opin Urol, 2021. 31: 354.
https://www.ncbi.nlm.nih.gov/pubmed/34009177

12.Rai, B.P., et al. Systematic Review of the Incidence of and Risk Factors for Urothelial Cancers and Renal Cell Carcinoma Among Patients with Haematuria. Eur Urol, 2022. 82: 182.
https://www.ncbi.nlm.nih.gov/pubmed/35393159

13.Margulis, V., et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer, 2009. 115: 1224.
https://www.ncbi.nlm.nih.gov/pubmed/19156917

14.Catto, J.W.F., et al. Diagnosis, treatment and survival from bladder, upper urinary tract, and urethral cancers: real-world findings from NHS England between 2013 and 2019. BJU Int, 2023. 131: 734.
https://www.ncbi.nlm.nih.gov/pubmed/36680312

15.Herout, R., et al. Upper tract urothelial carcinoma in Germany: epidemiological data and surgical treatment trends in a total population analysis from 2006 to 2019. World J Urol, 2023. 41: 127.
https://www.ncbi.nlm.nih.gov/pubmed/36445373

16.Aziz, A., et al. Stage Migration for Upper Tract Urothelial Cell Carcinoma. Clin Genitourin Cancer, 2021. 19: e184.
https://www.ncbi.nlm.nih.gov/pubmed/33153919

17.Browne, B.M., et al. An Analysis of Staging and Treatment Trends for Upper Tract Urothelial Carcinoma in the National Cancer Database. Clin Genitourin Cancer, 2018. 16: e743.
https://www.ncbi.nlm.nih.gov/pubmed/29506950

18.van Doeveren, T., et al. Rising incidence rates and unaltered survival rates for primary upper urinary tract urothelial carcinoma: a Dutch population-based study from 1993 to 2017. BJU Int, 2021. 128: 343.
https://www.ncbi.nlm.nih.gov/pubmed/33690922

19.Green, D.A., et al. Urothelial carcinoma of the bladder and the upper tract: disparate twins. J Urol, 2013. 189: 1214.
https://www.ncbi.nlm.nih.gov/pubmed/23023150

20.Otto, W., et al. Concomitant carcinoma in situ as an independent prognostic parameter for recurrence and survival in upper tract urothelial carcinoma: a multicenter analysis of 772 patients. World J Urol, 2011. 29: 487.
https://www.ncbi.nlm.nih.gov/pubmed/21249372

21.Liedberg, F., et al. Diagnostic pathways and treatment strategies in upper tract urothelial carcinoma in Sweden between 2015 and 2021: a population-based survey. Scand J Urol, 2024. 59: 19.
https://www.ncbi.nlm.nih.gov/pubmed/38226846

22.Cosentino, M., et al. Upper urinary tract urothelial cell carcinoma: location as a predictive factor for concomitant bladder carcinoma. World J Urol, 2013. 31: 141.
https://www.ncbi.nlm.nih.gov/pubmed/22552732

23.Singla, N., et al. A Multi-Institutional Comparison of Clinicopathological Characteristics and Oncologic Outcomes of Upper Tract Urothelial Carcinoma in China and the United States. J Urol, 2017. 197: 1208.
https://www.ncbi.nlm.nih.gov/pubmed/27887951

24.Herr, H.W. Extravesical tumor relapse in patients with superficial bladder tumors. J Clin Oncol, 1998. 16: 1099.
https://www.ncbi.nlm.nih.gov/pubmed/9508196

25.Miller, E.B., et al. Upper tract transitional cell carcinoma following treatment of superficial bladder cancer with BCG. Urology, 1993. 42: 26.
https://www.ncbi.nlm.nih.gov/pubmed/8328123

26.Nishiyama, N., et al. Upper tract urothelial carcinoma following intravesical bacillus Calmette-Guerin therapy for nonmuscle-invasive bladder cancer: Results from a multi-institutional retrospective study. Urol Oncol, 2018. 36: 306 e9.
https://www.ncbi.nlm.nih.gov/pubmed/29550096

27.Sanderson, K.M., et al. Upper urinary tract tumour after radical cystectomy for transitional cell carcinoma of the bladder: an update on the risk factors, surveillance regimens and treatments. BJU Int, 2007. 100: 11.
https://www.ncbi.nlm.nih.gov/pubmed/17428248

28.Ayyathurai, R., et al. Monitoring of the upper urinary tract in patients with bladder cancer. Indian J Urol, 2011. 27: 238.
https://www.ncbi.nlm.nih.gov/pubmed/21814316

29.Miyake, H., et al. A clinicopathological study of bladder cancer associated with upper urinary tract cancer. BJU Int, 2000. 85: 37.
https://www.ncbi.nlm.nih.gov/pubmed/10619943

30.Zuo, W., et al. Clinical, Prognosis, and Treatment Effect Features Analysis of Metachronous and Synchronous UTUC and BUC. Clin Genitourin Cancer, 2024. 22: 102192.
https://www.ncbi.nlm.nih.gov/pubmed/39261258

31.Guan, B., et al. Long-term impact of synchronous and metachronous bladder cancer on prognosis after radical nephroureterectomy for upper urinary tract urothelial carcinoma: results from a large population-based cohort in China. Int J Surg, 2025. 111: 7363.
https://www.ncbi.nlm.nih.gov/pubmed/40607984

32.Seisen, T., et al. A Systematic Review and Meta-analysis of Clinicopathologic Factors Linked to Intravesical Recurrence After Radical Nephroureterectomy to Treat Upper Tract Urothelial Carcinoma. Eur Urol, 2015. 67: 1122.
https://www.ncbi.nlm.nih.gov/pubmed/25488681

33.Li, W.M., et al. Oncologic outcomes following three different approaches to the distal ureter and bladder cuff in nephroureterectomy for primary upper urinary tract urothelial carcinoma. Eur Urol, 2010. 57: 963.
https://www.ncbi.nlm.nih.gov/pubmed/20079965

34.Audenet, F., et al. Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma. Clin Cancer Res, 2019. 25: 967.
https://www.ncbi.nlm.nih.gov/pubmed/30352907

35.Colin, P., et al. Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract. BJU Int, 2009. 104: 1436.
https://www.ncbi.nlm.nih.gov/pubmed/19689473

36.Dickman, K.G., et al., Epidemiology and Risk Factors for Upper Urinary Urothelial Cancers, in Upper Tract Urothelial Carcinoma, In: Shariat S., et al., Editors. 2015, Springer: New York, NY, USA.
https://link.springer.com/chapter/10.1007/978-1-4939-1501-9_1

37.McLaughlin, J.K., et al. Cigarette smoking and cancers of the renal pelvis and ureter. Cancer Res, 1992. 52: 254.
https://www.ncbi.nlm.nih.gov/pubmed/1728398

38.Crivelli, J.J., et al. Effect of smoking on outcomes of urothelial carcinoma: a systematic review of the literature. Eur Urol, 2014. 65: 742.
https://www.ncbi.nlm.nih.gov/pubmed/23810104

39.Grollman, A.P. Aristolochic acid nephropathy: Harbinger of a global iatrogenic disease. Environ Mol Mutagen, 2013. 54: 1.
https://www.ncbi.nlm.nih.gov/pubmed/23238808

40.National Toxicology Program. Aristolochic acids. Rep Carcinog, 2011. 12: 45.
https://www.ncbi.nlm.nih.gov/pubmed/21822318

41.Cosyns, J.P. Aristolochic acid and ‘Chinese herbs nephropathy’: a review of the evidence to date. Drug Saf, 2003. 26: 33.
https://www.ncbi.nlm.nih.gov/pubmed/12495362

42.Rosenquist, T.A., et al. Mutational signature of aristolochic acid: Clue to the recognition of a global disease. DNA Repair (Amst), 2016. 44: 205.
https://www.ncbi.nlm.nih.gov/pubmed/27237586

43.Sidorenko, V.S., et al. Bioactivation of the human carcinogen aristolochic acid. Carcinogenesis, 2014. 35: 1814.
https://www.ncbi.nlm.nih.gov/pubmed/24743514

44.Siegel, R.L., et al. Cancer Statistics, 2021. CA Cancer J Clin, 2021. 71: 7.
https://www.ncbi.nlm.nih.gov/pubmed/33433946

45.Hoang, M.L., et al. Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing. Sci Transl Med, 2013. 5: 197ra102.
https://www.ncbi.nlm.nih.gov/pubmed/23926200

46.Jelakovic, B., et al. Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid. Kidney Int, 2012. 81: 559.
https://www.ncbi.nlm.nih.gov/pubmed/22071594

47.Chen, C.H., et al. Aristolochic acid-associated urothelial cancer in Taiwan. Proc Natl Acad Sci U S A, 2012. 109: 8241.
https://www.ncbi.nlm.nih.gov/pubmed/22493262

48.Nortier, J.L., et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med, 2000. 342: 1686.
https://www.ncbi.nlm.nih.gov/pubmed/10841870

49.Huang, C.C., et al. Gender Is a Significant Prognostic Factor for Upper Tract Urothelial Carcinoma: A Large Hospital-Based Cancer Registry Study in an Endemic Area. Front Oncol, 2019. 9: 157.
https://www.ncbi.nlm.nih.gov/pubmed/30949449

50.Xiong, G., et al. Aristolochic acid containing herbs induce gender-related oncological differences in upper tract urothelial carcinoma patients. Cancer Manag Res, 2018. 10: 6627.
https://www.ncbi.nlm.nih.gov/pubmed/30584358

51.Chen, C.H., Arsenics and urothelial carcinoma, in Hazards of Environmental Arsenic Poisoning from Epidemic to Pandemic, C.H.Y. Chen C.J., Editor. 2011, World Scientific: Taipei.
https://www.worldscientific.com/worldscibooks/10.1142/7569

52.Lopez, J.F., et al. Arsenic exposure is associated with significant upper tract urothelial carcinoma health care needs and elevated mortality rates. Urol Oncol, 2020. 38: 638 e7.
https://www.ncbi.nlm.nih.gov/pubmed/32088105

53.Jhuang, J.R., et al. Reduced burden of Arsenic-Related cancers after water mitigation in Taiwan. Environ Int, 2024. 185: 108542.
https://www.ncbi.nlm.nih.gov/pubmed/38461779

54.Chen, C.H., et al. Additive Effects of Arsenic and Aristolochic Acid in Chemical Carcinogenesis of Upper Urinary Tract Urothelium. Cancer Epidemiol Biomarkers Prev, 2021. 30: 317.
https://www.ncbi.nlm.nih.gov/pubmed/33277322

55.Zaitsu, M., et al. Alcohol consumption and risk of upper-tract urothelial cancer. Cancer Epidemiol, 2017. 48: 36.
https://www.ncbi.nlm.nih.gov/pubmed/28364670

56.Koornstra, J.J., et al. Management of extracolonic tumours in patients with Lynch syndrome. Lancet Oncol, 2009. 10: 400.
https://www.ncbi.nlm.nih.gov/pubmed/19341971

57.Ju, J.Y., et al. Universal Lynch Syndrome Screening Should be Performed in All Upper Tract Urothelial Carcinomas. Am J Surg Pathol, 2018. 42: 1549.
https://www.ncbi.nlm.nih.gov/pubmed/30148743

58.Chandran, E.B.A., et al. Mismatch repair deficiency and microsatellite instability in urothelial carcinoma: a systematic review and meta-analysis. BMJ Oncol, 2024. 3(1): e000335.
https://www.ncbi.nlm.nih.gov/pubmed/39086924

59.Kastrinos, F., et al. Development and Validation of the PREMM(5) Model for Comprehensive Risk Assessment of Lynch Syndrome. J Clin Oncol, 2017. 35: 2165.
https://www.ncbi.nlm.nih.gov/pubmed/28489507

60.Vasen, H.F., et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology, 1999. 116: 1453.
https://www.ncbi.nlm.nih.gov/pubmed/10348829

61.Metcalfe, M.J., et al. Universal Point of Care Testing for Lynch Syndrome in Patients with Upper Tract Urothelial Carcinoma. J Urol, 2018. 199: 60.
https://www.ncbi.nlm.nih.gov/pubmed/28797715

62.Roupret, M., et al. Microsatellite instability as indicator of MSH2 gene mutation in patients with upper urinary tract transitional cell carcinoma. J Med Genet, 2004. 41: e91.
https://www.ncbi.nlm.nih.gov/pubmed/15235034

63.Audenet, F., et al. A proportion of hereditary upper urinary tract urothelial carcinomas are misclassified as sporadic according to a multi-institutional database analysis: proposal of patient-specific risk identification tool. BJU Int, 2012. 110: E583.
https://www.ncbi.nlm.nih.gov/pubmed/22703159

64.Roupret, M., et al. Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (lynch syndrome) tumor spectrum. Eur Urol, 2008. 54: 1226.
https://www.ncbi.nlm.nih.gov/pubmed/18715695

65.Acher, P., et al. Towards a rational strategy for the surveillance of patients with Lynch syndrome (hereditary non-polyposis colon cancer) for upper tract transitional cell carcinoma. BJU Int, 2010. 106: 300.
https://www.ncbi.nlm.nih.gov/pubmed/20553255

66.Gabriel, P.E., et al. A collaborative review of the microsatellite instability/deficient mismatch repair phenotype in patients with upper tract urothelial carcinoma. BJU Int, 2024. 134: 723.
https://www.ncbi.nlm.nih.gov/pubmed/38813615

67.Gayhart, M.G., et al. Universal Mismatch Repair Protein Screening in Upper Tract Urothelial Carcinoma. Am J Clin Pathol, 2020. 154: 792.
https://www.ncbi.nlm.nih.gov/pubmed/32789450

68.Schneider, B., et al. Loss of Mismatch-repair Protein Expression and Microsatellite Instability in Upper Tract Urothelial Carcinoma and Clinicopathologic Implications. Clin Genitourin Cancer, 2020. 18: e563.
https://www.ncbi.nlm.nih.gov/pubmed/32340874

69.Ito, T., et al. Prevalence of Lynch syndrome among patients with upper urinary tract carcinoma in a Japanese hospital-based population. Jpn J Clin Oncol, 2020. 50: 80.
https://www.ncbi.nlm.nih.gov/pubmed/31665498

70.Rasmussen, M., et al. Immunohistochemical Screening of Upper Tract Urothelial Carcinomas for Lynch Syndrome Diagnostics: A Systematic Review. Urology, 2022. 165: 44.
https://www.ncbi.nlm.nih.gov/pubmed/35217028

71.Roupret, M., et al. Genetic variability in 8q24 confers susceptibility to urothelial carcinoma of the upper urinary tract and is linked with patterns of disease aggressiveness at diagnosis. J Urol, 2012. 187: 424.
https://www.ncbi.nlm.nih.gov/pubmed/22177160

72.Martin, C., et al. Familial Cancer Clustering in Urothelial Cancer: A Population-Based Case-Control Study. J Natl Cancer Inst, 2018. 110: 527.
https://www.ncbi.nlm.nih.gov/pubmed/29228305

73.Kiss, B., et al. Stenting Prior to Cystectomy is an Independent Risk Factor for Upper Urinary Tract Recurrence. J Urol, 2017. 198: 1263.
https://www.ncbi.nlm.nih.gov/pubmed/28603003

74.Sountoulides, P., et al. Does Ureteral Stenting Increase the Risk of Metachronous Upper Tract Urothelial Carcinoma in Patients with Bladder Tumors? A Systematic Review and Meta-analysis. J Urol, 2021. 205: 956.
https://www.ncbi.nlm.nih.gov/pubmed/33284711

75.Sakano, S., et al. Impact of variant histology on disease aggressiveness and outcome after nephroureterectomy in Japanese patients with upper tract urothelial carcinoma. Int J Clin Oncol, 2015. 20: 362.
https://www.ncbi.nlm.nih.gov/pubmed/24964974

76.Ouzzane, A., et al. Small cell carcinoma of the upper urinary tract (UUT-SCC): report of a rare entity and systematic review of the literature. Cancer Treat Rev, 2011. 37: 366.
https://www.ncbi.nlm.nih.gov/pubmed/21257269

77.Krajewski, W., et al. Impact of Histological Subtypes/Divergent Differentiation on Clinicopathological and Oncological Outcomes for Patients with Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy: A Comprehensive Updated Systematic Review and Meta-analysis. Eur Urol Oncol, 2025. 8: 1126.
https://www.ncbi.nlm.nih.gov/pubmed/40221279

78.Perez-Montiel, D., et al. High-grade urothelial carcinoma of the renal pelvis: clinicopathologic study of 108 cases with emphasis on unusual morphologic variants. Mod Pathol, 2006. 19: 494.
https://www.ncbi.nlm.nih.gov/pubmed/16474378

79.Desai, F.S., et al. Retrospective Evaluation of Risk Factors and Immunohistochemical Findings for Pre-Neoplastic and Neoplastic lesions of Upper Urinary Tract in Patients with Chronic Nephrolithiasis. Asian Pac J Cancer Prev, 2015. 16: 8293.
https://www.ncbi.nlm.nih.gov/pubmed/26745075

80.Mori, K., et al. Prognostic Value of Variant Histology in Upper Tract Urothelial Carcinoma Treated with Nephroureterectomy: A Systematic Review and Meta-Analysis. J Urol, 2020. 203: 1075.
https://www.ncbi.nlm.nih.gov/pubmed/31479406

81.Zamboni, S., et al. Incidence and survival outcomes in patients with upper urinary tract urothelial carcinoma diagnosed with variant histology and treated with nephroureterectomy. BJU Int, 2019. 124: 738.
https://www.ncbi.nlm.nih.gov/pubmed/30908835

82.Kim, J.K., et al. Variant histology as a significant predictor of survival after radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma. Urol Oncol, 2017. 35: 458 e9.
https://www.ncbi.nlm.nih.gov/pubmed/28347659

83.Bang, H., et al. Clinicopathologic study of 60 cases of urothelial neoplasms with inverted growth patterns: Reclassification by international consultation on urologic disease (ICUD) recommendations. Ann Diagn Pathol, 2020. 44: 151433.
https://www.ncbi.nlm.nih.gov/pubmed/31785538

84.Urakami, S., et al. Clinicopathological characteristics of patients with upper urinary tract urothelial cancer with loss of immunohistochemical expression of the DNA mismatch repair proteins in universal screening. Int J Urol, 2018. 25: 151.
https://www.ncbi.nlm.nih.gov/pubmed/29164703

85.Malouf, G.G., et al. Unique Transcriptomic Profile of Collecting Duct Carcinomas Relative to Upper Tract Urothelial Carcinomas and other Kidney Carcinomas. Sci Rep, 2016. 6: 30988.
https://www.ncbi.nlm.nih.gov/pubmed/27484008

86.Hassler, M.R., et al. Molecular Characterization of Upper Tract Urothelial Carcinoma in the Era of Next-generation Sequencing: A Systematic Review of the Current Literature. Eur Urol, 2020. 78: 209.
https://www.ncbi.nlm.nih.gov/pubmed/32571725

87.Moss, T.J., et al. Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma. Eur Urol, 2017. 72: 641.
https://www.ncbi.nlm.nih.gov/pubmed/28601352

88.Kim, K., et al. Molecular Heterogeneity and Immune Infiltration Drive Clinical Outcomes in Upper Tract Urothelial Carcinoma. Eur Urol, 2025. 87: 342.
https://www.ncbi.nlm.nih.gov/pubmed/39550333

89.Eva, C., et al. Updates on Urothelial Carcinoma of the Upper Urinary Tract with a Focus on Molecular Findings. Surg Pathol Clin, 2025. 18: 53.
https://www.ncbi.nlm.nih.gov/pubmed/39890309

90.Robinson, B.D., et al. Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nat Commun, 2019. 10: 2977.
https://www.ncbi.nlm.nih.gov/pubmed/31278255

91.Fujii, Y., et al. Molecular classification and diagnostics of upper urinary tract urothelial carcinoma. Cancer Cell, 2021. 39: 793.
https://www.ncbi.nlm.nih.gov/pubmed/34129823

92.Shigeta, K., et al. Profiling Fibroblast Growth Factor Receptor 3 Expression Based on the Immune Microenvironment in Upper Tract Urothelial Carcinoma. Eur Urol Oncol, 2024. 7: 1338.
https://www.ncbi.nlm.nih.gov/pubmed/38320909

93.Soukup, V., et al. Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review. Eur Urol, 2017. 72: 801.
https://www.ncbi.nlm.nih.gov/pubmed/28457661

94.Subiela, J.D., et al. Diagnostic accuracy of ureteroscopic biopsy in predicting stage and grade at final pathology in upper tract urothelial carcinoma: Systematic review and meta-analysis. Eur J Surg Oncol, 2020. 46: 1989.
https://www.ncbi.nlm.nih.gov/pubmed/32674841

95.Brierley, J.D., et al., TNM Classification of Malignant Tumours. 9th ed. 2025.
https://books.google.nl/books?id=WeJhEQAAQBAJ&amp

96.WHO Classification of Tumours, WHO Classification of Tumours of the Urinary System and Male Genital Organs. 3rd ed. Vol. 7. 2004, Lyon (France).
https://publications.iarc.who.int/Book-And-Report-Series/Who-Classification-Of-Tumours/Pathology-And-Genetics-Of-Tumours-Of-The-Urinary-System-And-Male-Genital-Organs-2004

97.WHO Classification of Tumours, WHO Classification of Tumours of the Urinary System and Male Genital Organs. 4th ed. Vol. 8. 2016, Lyon (France).
https://publications.iarc.who.int/Book-And-Report-Series/Who-Classification-Of-Tumours/WHO-Classification-Of-Tumours-Of-The-Urinary-System-And-Male-Genital-Organs-2016

98.WHO Classification of Tumours, WHO Classification of Tumours of the Urinary System and Male Genital Organs. 5th ed. Vol. 8. 2022, Lyon (France).
https://publications.iarc.who.int/Book-And-Report-Series/Who-Classification-Of-Tumours/Urinary-And-Male-Genital-Tumours-2022

99.Raman, J.D., et al. Does preoperative symptom classification impact prognosis in patients with clinically localized upper-tract urothelial carcinoma managed by radical nephroureterectomy? Urol Oncol, 2011. 29: 716.
https://www.ncbi.nlm.nih.gov/pubmed/20056458

100.Cowan, N.C., et al. Multidetector computed tomography urography for diagnosing upper urinary tract urothelial tumour. BJU Int, 2007. 99: 1363.
https://www.ncbi.nlm.nih.gov/pubmed/17428251

101.Janisch, F., et al. Diagnostic performance of multidetector computed tomographic (MDCTU) in upper tract urothelial carcinoma (UTUC): a systematic review and meta-analysis. World J Urol, 2020. 38: 1165.
https://www.ncbi.nlm.nih.gov/pubmed/31321509

102.Verhoest, G., et al. Predictive factors of recurrence and survival of upper tract urothelial carcinomas. World J Urol, 2011. 29: 495.
https://www.ncbi.nlm.nih.gov/pubmed/21681525

103.Pallauf, M., et al. Diagnostic Accuracy of Clinical Lymph Node Staging for Upper Tract Urothelial Cancer Patients: A Multicenter, Retrospective, Observational Study. J Urol, 2023. 209: 515.
https://www.ncbi.nlm.nih.gov/pubmed/36475808

104.Takahashi, N., et al. Gadolinium enhanced magnetic resonance urography for upper urinary tract malignancy. J Urol, 2010. 183: 1330.
https://www.ncbi.nlm.nih.gov/pubmed/20171676

105.Razavi, S.A., et al. Comparative effectiveness of imaging modalities for the diagnosis of upper and lower urinary tract malignancy: a critically appraised topic. Acad Radiol, 2012. 19: 1134.
https://www.ncbi.nlm.nih.gov/pubmed/22717592

106.Voskuilen, C.S., et al. Diagnostic Value of (18)F-fluorodeoxyglucose Positron Emission Tomography with Computed Tomography for Lymph Node Staging in Patients with Upper Tract Urothelial Carcinoma. Eur Urol Oncol, 2020. 3: 73.
https://www.ncbi.nlm.nih.gov/pubmed/31591037

107.The Paris System for Reporting Urinary Cytology. 2nd ed, ed. E.M. Wojcik, et al. 2022.
https://link.springer.com/book/10.1007/978-3-030-88686-8

108.Messer, J., et al. Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. BJU Int, 2011. 108: 701.
https://www.ncbi.nlm.nih.gov/pubmed/21320275

109.Malm, C., et al. Diagnostic accuracy of upper tract urothelial carcinoma: how samples are collected matters. Scand J Urol, 2017. 51: 137.
https://www.ncbi.nlm.nih.gov/pubmed/28385123

110.Wang, L.J., et al. Diagnostic accuracy of transitional cell carcinoma on multidetector computerized tomography urography in patients with gross hematuria. J Urol, 2009. 181: 524.
https://www.ncbi.nlm.nih.gov/pubmed/19100576

111.Lee, K.S., et al. MR urography versus retrograde pyelography/ureteroscopy for the exclusion of upper urinary tract malignancy. Clin Radiol, 2010. 65: 185.
https://www.ncbi.nlm.nih.gov/pubmed/20152273

112.Zhang, H., et al. Large-scale Prospective Validation Study of a Multiplex RNA Urine Test for Noninvasive Detection of Upper Tract Urothelial Carcinoma. Eur Urol Oncol, 2024. 7: 1384.
https://www.ncbi.nlm.nih.gov/pubmed/38523018

113.Ghoreifi, A., et al. A Urine-based DNA Methylation Marker Test to Detect Upper Tract Urothelial Carcinoma: A Prospective Cohort Study. J Urol, 2023. 209: 854.
https://www.ncbi.nlm.nih.gov/pubmed/36795966

114.Monteiro-Reis, S., et al. Accurate detection of upper tract urothelial carcinoma in tissue and urine by means of quantitative GDF15, TMEFF2 and VIM promoter methylation. Eur J Cancer, 2014. 50: 226.
https://www.ncbi.nlm.nih.gov/pubmed/24100025

115.Territo, A., et al. DNA Methylation Urine Biomarkers Test in the Diagnosis of Upper Tract Urothelial Carcinoma: Results from a Single-Center Prospective Clinical Trial. J Urol, 2022. 208: 570.
https://www.ncbi.nlm.nih.gov/pubmed/35549312

116.Pycha, S., et al. Diagnostic value of Xpert(R) BC Detection, Bladder Epicheck(R), Urovysion(R) FISH and cytology in the detection of upper urinary tract urothelial carcinoma. World J Urol, 2023. 41: 1323.
https://www.ncbi.nlm.nih.gov/pubmed/36929411

117.Palermo, M., et al. Prospective evaluation of the RT-PCR based urinary marker Bladder Epicheck(R) as a diagnostic tool in upper urinary tract tumor. Minerva Urol Nephrol, 2024. 76: 195.
https://www.ncbi.nlm.nih.gov/pubmed/38498297

118.Bier, S., et al. Performance of Urinary Markers for Detection of Upper Tract Urothelial Carcinoma: Is Upper Tract Urine More Accurate than Urine from the Bladder? Dis Markers, 2018. 2018: 5823870.
https://www.ncbi.nlm.nih.gov/pubmed/29651327

119.D’Elia, C., et al. Xpert(R) bladder cancer detection as a diagnostic tool in upper urinary tract urothelial carcinoma: preliminary results. Ther Adv Urol, 2022. 14: 17562872221090320.
https://www.ncbi.nlm.nih.gov/pubmed/35450126

120.Gruschwitz, T., et al. FISH analysis of washing urine from the upper urinary tract for the detection of urothelial cancers. Int Urol Nephrol, 2014. 46: 1769.
https://www.ncbi.nlm.nih.gov/pubmed/24752865

121.Pierconti, F., et al. Upper urothelial tract high-grade carcinoma: comparison of urine cytology and DNA methylation analysis in urinary samples. Hum Pathol, 2021. 118: 42.
https://www.ncbi.nlm.nih.gov/pubmed/34582934

122.Huelster, H.L., et al. Novel Use of Circulating Tumor DNA to Identify Muscle-invasive and Non-organ-confined Upper Tract Urothelial Carcinoma. Eur Urol, 2024. 85: 283.
https://www.ncbi.nlm.nih.gov/pubmed/37802683

123.Rojas, C.P., et al. Low biopsy volume in ureteroscopy does not affect tumor biopsy grading in upper tract urothelial carcinoma. Urol Oncol, 2013. 31: 1696.
https://www.ncbi.nlm.nih.gov/pubmed/22819696

124.Mori, K., et al. Discordance Between Clinical and Pathological Staging and Grading in Upper Tract Urothelial Carcinoma. Clin Genitourin Cancer, 2022. 20: 95 e1.
https://www.ncbi.nlm.nih.gov/pubmed/34764007

125.Smith, A.K., et al. Inadequacy of biopsy for diagnosis of upper tract urothelial carcinoma: implications for conservative management. Urology, 2011. 78: 82.
https://www.ncbi.nlm.nih.gov/pubmed/21550642

126.Ishikawa, S., et al. Impact of diagnostic ureteroscopy on intravesical recurrence and survival in patients with urothelial carcinoma of the upper urinary tract. J Urol, 2010. 184: 883.
https://www.ncbi.nlm.nih.gov/pubmed/20643446

127.Clements, T., et al. High-grade ureteroscopic biopsy is associated with advanced pathology of upper-tract urothelial carcinoma tumors at definitive surgical resection. J Endourol, 2012. 26: 398.
https://www.ncbi.nlm.nih.gov/pubmed/22192113

128.Brien, J.C., et al. Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma. J Urol, 2010. 184: 69.
https://www.ncbi.nlm.nih.gov/pubmed/20478585

129.Sharma, V., et al. The Impact of Upper Tract Urothelial Carcinoma Diagnostic Modality on Intravesical Recurrence after Radical Nephroureterectomy: A Single Institution Series and Updated Meta-Analysis. J Urol, 2021. 206: 558.
https://www.ncbi.nlm.nih.gov/pubmed/33908802

130.Nowak, L., et al. The Impact of Diagnostic Ureteroscopy Prior to Radical Nephroureterectomy on Oncological Outcomes in Patients with Upper Tract Urothelial Carcinoma: A Comprehensive Systematic Review and Meta-Analysis. J Clin Med, 2021. 10(18): 4197.
https://www.ncbi.nlm.nih.gov/pubmed/34575307

131.Bus, M.T., et al. Optical diagnostics for upper urinary tract urothelial cancer: technology, thresholds, and clinical applications. J Endourol, 2015. 29: 113.
https://www.ncbi.nlm.nih.gov/pubmed/25178057

132.Knoedler, J.J., et al. Advances in the management of upper tract urothelial carcinoma: improved endoscopic management through better diagnostics. Ther Adv Urol, 2018. 10: 421.
https://www.ncbi.nlm.nih.gov/pubmed/30574202

133.Breda, A., et al. Correlation Between Confocal Laser Endomicroscopy (Cellvizio((R))) and Histological Grading of Upper Tract Urothelial Carcinoma: A Step Forward for a Better Selection of Patients Suitable for Conservative Management. Eur Urol Focus, 2018. 4: 954.
https://www.ncbi.nlm.nih.gov/pubmed/28753800

134.Bus, M.T., et al. Optical Coherence Tomography as a Tool for In Vivo Staging and Grading of Upper Urinary Tract Urothelial Carcinoma: A Study of Diagnostic Accuracy. J Urol, 2016. 196: 1749.
https://www.ncbi.nlm.nih.gov/pubmed/27475968

135.Pouessel, D., et al. Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment. Ann Oncol, 2016. 27: 1311.
https://www.ncbi.nlm.nih.gov/pubmed/27091807

136.Loriot, Y., et al. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. N Engl J Med, 2019. 381: 338.
https://www.ncbi.nlm.nih.gov/pubmed/31340094

137.Colla Ruvolo, C., et al. Incidence and Survival Rates of Contemporary Patients with Invasive Upper Tract Urothelial Carcinoma. Eur Urol Oncol, 2021. 4: 792.
https://www.ncbi.nlm.nih.gov/pubmed/33293235

138.Mbeutcha, A., et al. Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review. World J Urol, 2017. 35: 337.
https://www.ncbi.nlm.nih.gov/pubmed/27101100

139.Liu, J., et al. Prognostic models for upper urinary tract urothelial carcinoma patients after radical nephroureterectomy based on a novel systemic immune-inflammation score with machine learning. BMC Cancer, 2023. 23: 574.
https://www.ncbi.nlm.nih.gov/pubmed/37349696

140.Rosiello, G., et al. Contemporary conditional cancer-specific survival after radical nephroureterectomy in patients with nonmetastatic urothelial carcinoma of upper urinary tract. J Surg Oncol, 2020. 121: 1154.
https://www.ncbi.nlm.nih.gov/pubmed/32107785

141.Raman, J.D., et al. Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy. Eur Urol, 2010. 57: 1072.
https://www.ncbi.nlm.nih.gov/pubmed/19619934

142.Yu, J., et al. Impact of squamous differentiation on intravesical recurrence and prognosis of patients with upper tract urothelial carcinoma. Ann Transl Med, 2019. 7: 377.
https://www.ncbi.nlm.nih.gov/pubmed/31555691

143.McCoy, J.G., et al. Computerized tomography for detection and staging of localized and pathologically defined upper tract urothelial tumors. J Urol, 1991. 146: 1500.
https://www.ncbi.nlm.nih.gov/pubmed/1942327

144.Almas, B., et al. Preoperative predictors of pathological tumour stage and prognosis may be used when selecting candidates for intensified treatment in upper tract urothelial carcinoma. Scand J Urol, 2021. 55: 100.
https://www.ncbi.nlm.nih.gov/pubmed/33517813

145.Ouzzane, A., et al. Ureteral and multifocal tumours have worse prognosis than renal pelvic tumours in urothelial carcinoma of the upper urinary tract treated by nephroureterectomy. Eur Urol, 2011. 60: 1258.
https://www.ncbi.nlm.nih.gov/pubmed/21665356

146.Yafi, F.A., et al. Impact of tumour location versus multifocality in patients with upper tract urothelial carcinoma treated with nephroureterectomy and bladder cuff excision: a homogeneous series without perioperative chemotherapy. BJU Int, 2012. 110: E7.
https://www.ncbi.nlm.nih.gov/pubmed/22177329

147.Hurel, S., et al. Influence of preoperative factors on the oncologic outcome for upper urinary tract urothelial carcinoma after radical nephroureterectomy. World J Urol, 2015. 33: 335.
https://www.ncbi.nlm.nih.gov/pubmed/24810657

148.Chromecki, T.F., et al. The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy. Eur Urol, 2012. 61: 245.
https://www.ncbi.nlm.nih.gov/pubmed/21975249

149.Fradet, V., et al. Risk factors for bladder cancer recurrence after nephroureterectomy for upper tract urothelial tumors: results from the Canadian Upper Tract Collaboration. Urol Oncol, 2014. 32: 839.
https://www.ncbi.nlm.nih.gov/pubmed/24856978

150.Favaretto, R.L., et al. The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center. Eur Urol, 2010. 58: 574.
https://www.ncbi.nlm.nih.gov/pubmed/20637540

151.Messer, J.C., et al. Multi-institutional validation of the ability of preoperative hydronephrosis to predict advanced pathologic tumor stage in upper-tract urothelial carcinoma. Urol Oncol, 2013. 31: 904.
https://www.ncbi.nlm.nih.gov/pubmed/21906967

152.Ito, Y., et al. Preoperative hydronephrosis grade independently predicts worse pathological outcomes in patients undergoing nephroureterectomy for upper tract urothelial carcinoma. J Urol, 2011. 185: 1621.
https://www.ncbi.nlm.nih.gov/pubmed/21419429

153.Ye, T., et al. Prognostic Value of Preoperative Hydronephrosis in Patients Undergoing Radical Nephroureterectomy for Upper Tract Urinary Carcinoma: A Systematic Review and Meta-Analysis. Front Oncol, 2020. 10: 600511.
https://www.ncbi.nlm.nih.gov/pubmed/33425758

154.Ma, R., et al. Prognostic Value of Tumor Size in Patients with Upper Tract Urothelial Carcinoma: A Systematic Review and Meta-analysis. Eur Urol Open Sci, 2022. 42: 19.
https://www.ncbi.nlm.nih.gov/pubmed/35783990

155.Colla Ruvolo, C., et al. Tumor Size Predicts Muscle-invasive and Non-organ-confined Disease in Upper Tract Urothelial Carcinoma at Radical Nephroureterectomy. Eur Urol Focus, 2022. 8: 498.
https://www.ncbi.nlm.nih.gov/pubmed/33737024

156.Foerster, B., et al. The Performance of Tumor Size as Risk Stratification Parameter in Upper Tract Urothelial Carcinoma (UTUC). Clin Genitourin Cancer, 2021. 19: 272 e1.
https://www.ncbi.nlm.nih.gov/pubmed/33046411

157.Zhang, X., et al. Development and Validation of a Model for Predicting Intravesical Recurrence in Organ-confined Upper Urinary Tract Urothelial Carcinoma Patients after Radical Nephroureterectomy: a Retrospective Study in One Center with Long-term Follow-up. Pathol Oncol Res, 2020. 26: 1741.
https://www.ncbi.nlm.nih.gov/pubmed/31643022

158.Sheu, Z.L., et al. Tumor distribution affects bladder recurrence but not survival outcome of multifocal upper tract urothelial carcinoma treated with radical nephroureterectomy. Sci Rep, 2021. 11: 19059.
https://www.ncbi.nlm.nih.gov/pubmed/34561545

159.Marchioni, M., et al. Impact of diagnostic ureteroscopy on intravesical recurrence in patients undergoing radical nephroureterectomy for upper tract urothelial cancer: a systematic review and meta-analysis. BJU Int, 2017. 120: 313.
https://www.ncbi.nlm.nih.gov/pubmed/28621055

160.Guo, R.Q., et al. Impact of ureteroscopy before radical nephroureterectomy for upper tract urothelial carcinomas on oncological outcomes: a meta-analysis. BJU Int, 2018. 121: 184.
https://www.ncbi.nlm.nih.gov/pubmed/29032580

161.Liedberg, F., et al. Preoperative upper tract invasive diagnostic modalities are associated with intravesical recurrence following surgery for upper tract urothelial carcinoma: A population-based study. PLoS One, 2023. 18: e0281304.
https://www.ncbi.nlm.nih.gov/pubmed/36730353

162.Parmar, K., et al. Focused UTUC pathways with a risk-stratified approach to diagnostic ureteroscopy: is it the need of the hour? A retrospective cohort analysis. World J Urol, 2024. 42: 76.
https://www.ncbi.nlm.nih.gov/pubmed/38340192

163.Seisen, T., et al. Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel. Eur Urol, 2016. 70: 1052.
https://www.ncbi.nlm.nih.gov/pubmed/27477528

164.Slusarczyk, A., et al. Oncologic outcomes of patients treated with kidney-sparing surgery or radical nephroureterectomy for upper urinary tract urothelial cancer: a population-based study. Urol Oncol, 2024. 42: 22 e1.
https://www.ncbi.nlm.nih.gov/pubmed/37981503

165.Cutress, M.L., et al. Long-term endoscopic management of upper tract urothelial carcinoma: 20-year single-centre experience. BJU Int, 2012. 110: 1608.
https://www.ncbi.nlm.nih.gov/pubmed/22564677

166.Cutress, M.L., et al. Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review. BJU Int, 2012. 110: 614.
https://www.ncbi.nlm.nih.gov/pubmed/22471401

167.Villa, L., et al. Early repeated ureteroscopy within 6-8 weeks after a primary endoscopic treatment in patients with upper tract urothelial cell carcinoma: preliminary findings. World J Urol, 2016. 34: 1201.
https://www.ncbi.nlm.nih.gov/pubmed/26699629

168.Gallioli, A., et al. Oncologic Outcomes of Endoscopic Management of Upper Tract Urothelial Carcinoma: A Systematic Review and Pooled Analysis from the EAU-YAU Urothelial Working Group. Eur Urol Focus, 2025.
https://www.ncbi.nlm.nih.gov/pubmed/39894734

169.Vemana, G., et al. Survival Comparison Between Endoscopic and Surgical Management for Patients With Upper Tract Urothelial Cancer: A Matched Propensity Score Analysis Using Surveillance, Epidemiology and End Results-Medicare Data. Urology, 2016. 95: 115.
https://www.ncbi.nlm.nih.gov/pubmed/27233931

170.Kawada, T., et al. Oncologic and Safety Outcomes for Endoscopic Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: An Updated Systematic Review and Meta-analysis. Eur Urol Focus, 2023. 9: 236.
https://www.ncbi.nlm.nih.gov/pubmed/36463089

171.Cornu, J.N., et al. Oncologic control obtained after exclusive flexible ureteroscopic management of upper urinary tract urothelial cell carcinoma. World J Urol, 2010. 28: 151.
https://www.ncbi.nlm.nih.gov/pubmed/20044752

172.Villani, R., et al. With great power comes great risk: High ureteral stricture rate after high-power, high-frequency Thulium fiber laser lithotripsy in ureteroscopy. World J Urol, 2025. 43: 232.
https://www.ncbi.nlm.nih.gov/pubmed/40249411

173.Gallioli, A., et al. The importance of second-look ureteroscopy implementation in the conservative management of upper tract urothelial carcinoma. World J Urol, 2023. 41: 2743.
https://www.ncbi.nlm.nih.gov/pubmed/37668716

174.Roupret, M., et al. Upper urinary tract transitional cell carcinoma: recurrence rate after percutaneous endoscopic resection. Eur Urol, 2007. 51: 709.
https://www.ncbi.nlm.nih.gov/pubmed/16911852

175.Steffens, J., et al. Partial nephrectomy and autotransplantation with pyelovesicostomy for renal urothelial carcinoma in solitary kidneys: a clinical update. BJU Int, 2007. 99: 1020.
https://www.ncbi.nlm.nih.gov/pubmed/17309555

176.Ou, Y.C., et al. Long-term outcomes of total ureterectomy with ileal-ureteral substitution treatment for ureteral cancer: a single-center experience. BMC Urol, 2018. 18: 73.
https://www.ncbi.nlm.nih.gov/pubmed/30170590

177.Jeldres, C., et al. Segmental ureterectomy can safely be performed in patients with transitional cell carcinoma of the ureter. J Urol, 2010. 183: 1324.
https://www.ncbi.nlm.nih.gov/pubmed/20171666

178.Colin, P., et al. Comparison of oncological outcomes after segmental ureterectomy or radical nephroureterectomy in urothelial carcinomas of the upper urinary tract: results from a large French multicentre study. BJU Int, 2012. 110: 1134.
https://www.ncbi.nlm.nih.gov/pubmed/22394612

179.Abrate, A., et al. Segmental Ureterectomy Versus Radical Nephroureterectomy in Older Patients Treated for Upper Tract Urothelial Carcinoma. Clin Genitourin Cancer, 2022. 20: 381.
https://www.ncbi.nlm.nih.gov/pubmed/35125302

180.Giannarini, G., et al. Elective management of transitional cell carcinoma of the distal ureter: can kidney-sparing surgery be advised? BJU Int, 2007. 100: 264.
https://www.ncbi.nlm.nih.gov/pubmed/17532855

181.Silberstein, J.L., et al. Renal function and oncologic outcomes of parenchymal sparing ureteral resection versus radical nephroureterectomy for upper tract urothelial carcinoma. J Urol, 2012. 187: 429.
https://www.ncbi.nlm.nih.gov/pubmed/22177163

182.Matin, S.F., et al. Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final Report. J Urol, 2022. 207: 779.
https://www.ncbi.nlm.nih.gov/pubmed/34915741

183.Pierorazio, P.M., et al. Long-Term Outcomes of Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma With UGN-101, a Mitomycin Reverse Thermal Gel. J Urol, 2025. 213: 313.
https://www.ncbi.nlm.nih.gov/pubmed/39561384

184.Redrow, G.P., et al. Upper Urinary Tract Carcinoma In Situ: Current Knowledge, Future Direction. J Urol, 2017. 197: 287.
https://www.ncbi.nlm.nih.gov/pubmed/27664578

185.Giannarini, G., et al. Antegrade perfusion with bacillus Calmette-Guerin in patients with non-muscle-invasive urothelial carcinoma of the upper urinary tract: who may benefit? Eur Urol, 2011. 60: 955.
https://www.ncbi.nlm.nih.gov/pubmed/21807456

186.Seisen, T., et al. Risk-adapted strategy for the kidney-sparing management of upper tract tumours. Nat Rev Urol, 2015. 12: 155.
https://www.ncbi.nlm.nih.gov/pubmed/25708579

187.Irie, A., et al. Intravesical instillation of bacille Calmette-Guerin for carcinoma in situ of the urothelium involving the upper urinary tract using vesicoureteral reflux created by a double-pigtail catheter. Urology, 2002. 59: 53.
https://www.ncbi.nlm.nih.gov/pubmed/11796281

188.Yossepowitch, O., et al. Assessment of vesicoureteral reflux in patients with self-retaining ureteral stents: implications for upper urinary tract instillation. J Urol, 2005. 173: 890.
https://www.ncbi.nlm.nih.gov/pubmed/15711312

189.Foerster, B., et al. Endocavitary treatment for upper tract urothelial carcinoma: A meta-analysis of the current literature. Urol Oncol, 2019. 37: 430.
https://www.ncbi.nlm.nih.gov/pubmed/30846387

190.Gallioli, A., et al. Adjuvant Single-Dose Upper Urinary Tract Instillation of Mitomycin C After Therapeutic Ureteroscopy for Upper Tract Urothelial Carcinoma: A Single-Centre Prospective Non-Randomized Trial. J Endourol, 2020. 34: 573.
https://www.ncbi.nlm.nih.gov/pubmed/32164441

191.Veccia, A., et al. Robotic vs Laparoscopic Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Multicenter Propensity-Score Matched Pair “tetrafecta” Analysis (ROBUUST Collaborative Group). J Endourol, 2022. 36: 752.
https://www.ncbi.nlm.nih.gov/pubmed/35019760

192.Ji, R., et al. Robot-assisted vs. laparoscopic nephroureterectomy for upper urinary tract urothelial carcinoma: a systematic review and meta-analysis based on comparative studies. Front Oncol, 2022. 12: 964256.
https://www.ncbi.nlm.nih.gov/pubmed/35992849

193.Peyronnet, B., et al. Oncological Outcomes of Laparoscopic Nephroureterectomy Versus Open Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: An European Association of Urology Guidelines Systematic Review. Eur Urol Focus, 2019. 5: 205.
https://www.ncbi.nlm.nih.gov/pubmed/29154042

194.Rajan, K., et al. Oncological Efficacy of Robotic Nephroureterectomy vs. Open and Laparoscopic Nephroureterectomy for Suspected Non-Metastatic UTUC-A Systematic Review and Meta-Analysis. Cancers (Basel), 2023. 15(20): 4926.
https://www.ncbi.nlm.nih.gov/pubmed/37894293

195.Simone, G., et al. Laparoscopic versus open nephroureterectomy: perioperative and oncologic outcomes from a randomised prospective study. Eur Urol, 2009. 56: 520.
https://www.ncbi.nlm.nih.gov/pubmed/19560259

196.Zhu, P.Y., et al. Perioperative and oncologic outcomes of transperitoneal versus retroperitoneal laparoscopic nephroureterectomy for upper urinary tract urothelial carcinoma: a systematic review and pooled analysis of comparative outcomes. World J Surg Oncol, 2023. 21: 163.
https://www.ncbi.nlm.nih.gov/pubmed/37248555

197.Sparwasser, P., et al. First Comparison of Retroperitoneal Versus Transperitoneal Robot-Assisted Nephroureterectomy with Bladder Cuff: A Single Center Study. Ann Surg Oncol, 2023. 30: 4531.
https://www.ncbi.nlm.nih.gov/pubmed/37099087

198.Yamashita, S., et al. Efficacy of early ureteral ligation on prevention of intravesical recurrence after radical nephroureterectomy for upper urinary tract urothelial carcinoma: a prospective single-arm multicenter clinical trial. Jpn J Clin Oncol, 2017. 47: 870.
https://www.ncbi.nlm.nih.gov/pubmed/28903527

199.Xylinas, E., et al. Prediction of intravesical recurrence after radical nephroureterectomy: development of a clinical decision-making tool. Eur Urol, 2014. 65: 650.
https://www.ncbi.nlm.nih.gov/pubmed/24070577

200.Phe, V., et al. Does the surgical technique for management of the distal ureter influence the outcome after nephroureterectomy? BJU Int, 2011. 108: 130.
https://www.ncbi.nlm.nih.gov/pubmed/21070580

201.Xylinas, E., et al. Impact of distal ureter management on oncologic outcomes following radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol, 2014. 65: 210.
https://www.ncbi.nlm.nih.gov/pubmed/22579047

202.Dominguez-Escrig, J.L., et al. Potential Benefit of Lymph Node Dissection During Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the European Association of Urology Guidelines Panel on Non-muscle-invasive Bladder Cancer. Eur Urol Focus, 2019. 5: 224.
https://www.ncbi.nlm.nih.gov/pubmed/29158169

203.Kondo, T., et al. Template-based lymphadenectomy in urothelial carcinoma of the upper urinary tract: impact on patient survival. Int J Urol, 2010. 17: 848.
https://www.ncbi.nlm.nih.gov/pubmed/20812922

204.Dong, F., et al. Lymph node dissection could bring survival benefits to patients diagnosed with clinically node-negative upper urinary tract urothelial cancer: a population-based, propensity score-matched study. Int J Clin Oncol, 2019. 24: 296.
https://www.ncbi.nlm.nih.gov/pubmed/30334174

205.Lenis, A.T., et al. Role of surgical approach on lymph node dissection yield and survival in patients with upper tract urothelial carcinoma. Urol Oncol, 2018. 36: 9 e1.
https://www.ncbi.nlm.nih.gov/pubmed/29066013

206.Bobjer, J., et al. Location of Retroperitoneal Lymph Node Metastases in Upper Tract Urothelial Carcinoma: Results from a Prospective Lymph Node Mapping Study. Eur Urol Open Sci, 2023. 57: 37.
https://www.ncbi.nlm.nih.gov/pubmed/38020529

207.Matin, S.F., et al. Patterns of Lymphatic Metastases in Upper Tract Urothelial Carcinoma and Proposed Dissection Templates. J Urol, 2015. 194: 1567.
https://www.ncbi.nlm.nih.gov/pubmed/26094807

208.Kondo, T., et al. Template-based lymphadenectomy in urothelial carcinoma of the renal pelvis: a prospective study. Int J Urol, 2014. 21: 453.
https://www.ncbi.nlm.nih.gov/pubmed/24754341

209.Masson-Lecomte, A., et al. Oncological Outcomes of Distal Ureterectomy for High-Risk Urothelial Carcinoma: A Multicenter Study by The French Bladder Cancer Committee. Cancers (Basel), 2022. 14.
https://www.ncbi.nlm.nih.gov/pubmed/36358870

210.Lima, W., et al. The impact of routine frozen section analysis during nephroureterectomy or segmental ureterectomy for urothelial carcinoma on final surgical margin status and long-term oncologic outcome. Urol Oncol, 2023. 41: 357 e1.
https://www.ncbi.nlm.nih.gov/pubmed/37142451

211.Guan, B., et al. Segmental Resection with Ureteral Reimplantation vs Radical Nephroureterectomy with Bladder Cuff Removal for Urothelial Carcinoma of Distal Ureter: A Propensity Score Matching Study in a Large Chinese Center. J Endourol, 2025. 39: 105.
https://www.ncbi.nlm.nih.gov/pubmed/39886737

212.Moschini, M., et al. Trends of lymphadenectomy in upper tract urothelial carcinoma (UTUC) patients treated with radical nephroureterectomy. World J Urol, 2017. 35: 1541.
https://www.ncbi.nlm.nih.gov/pubmed/28247066

213.Zareba, P., et al. Association between lymph node yield and survival among patients undergoing radical nephroureterectomy for urothelial carcinoma of the upper tract. Cancer, 2017. 123: 1741.
https://www.ncbi.nlm.nih.gov/pubmed/28152158

214.Xylinas, E., et al. External validation of the pathological nodal staging score in upper tract urothelial carcinoma: A population-based study. Urol Oncol, 2017. 35: 33 e21.
https://www.ncbi.nlm.nih.gov/pubmed/27816402

215.Xylinas, E., et al. Prediction of true nodal status in patients with pathological lymph node negative upper tract urothelial carcinoma at radical nephroureterectomy. J Urol, 2013. 189: 468.
https://www.ncbi.nlm.nih.gov/pubmed/23253960

216.Guan, B., et al. Pattern and risk factors of local recurrence and intravesical recurrence after segmental ureterectomy for upper tract urothelial carcinoma. Urol Oncol, 2025. 43: 330 e11.
https://www.ncbi.nlm.nih.gov/pubmed/40187951

217.Villa, L., et al. Which Patients with Upper Tract Urothelial Carcinoma Can be Safely Treated with Flexible Ureteroscopy with Holmium:YAG Laser Photoablation? Long-Term Results from a High Volume Institution. J Urol, 2018. 199: 66.
https://www.ncbi.nlm.nih.gov/pubmed/28818526

218.Baboudjian, M., et al. Long-Term Oncologic Outcomes of Endoscopic Management of High-Risk Upper Tract Urothelial Carcinoma: The Fundacio Puigvert’s Experience. J Endourol, 2023. 37: 973.
https://www.ncbi.nlm.nih.gov/pubmed/37310884

219.Martini, A., et al. Pathological downstaging as a novel endpoint for the development of neoadjuvant chemotherapy for upper tract urothelial carcinoma. BJU Int, 2019. 124: 665.
https://www.ncbi.nlm.nih.gov/pubmed/30801918

220.Matin, S.F., et al. Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer, 2010. 116: 3127.
https://www.ncbi.nlm.nih.gov/pubmed/20564621

221.Liao, R.S., et al. Comparison of Pathological Stage in Patients Treated with and without Neoadjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma. J Urol, 2018. 200: 68.
https://www.ncbi.nlm.nih.gov/pubmed/29307680

222.Meng, X., et al. High Response Rates to Neoadjuvant Chemotherapy in High-Grade Upper Tract Urothelial Carcinoma. Urology, 2019. 129: 146.
https://www.ncbi.nlm.nih.gov/pubmed/30930207

223.Almassi, N., et al. Impact of Neoadjuvant Chemotherapy on Pathologic Response in Patients With Upper Tract Urothelial Carcinoma Undergoing Extirpative Surgery. Clin Genitourin Cancer, 2018. 16: e1237.
https://www.ncbi.nlm.nih.gov/pubmed/30217764

224.Venkat, S., et al. Novel nomograms to predict muscle invasion and lymph node metastasis in upper tract urothelial carcinoma. Urol Oncol, 2022. 40: 108 e11.
https://www.ncbi.nlm.nih.gov/pubmed/35034804

225.Kubota, Y., et al. Oncological outcomes of neoadjuvant chemotherapy in patients with locally advanced upper tract urothelial carcinoma: a multicenter study. Oncotarget, 2017. 8: 101500.
https://www.ncbi.nlm.nih.gov/pubmed/29254181

226.Hosogoe, S., et al. Platinum-based Neoadjuvant Chemotherapy Improves Oncological Outcomes in Patients with Locally Advanced Upper Tract Urothelial Carcinoma. Eur Urol Focus, 2018. 4: 946.
https://www.ncbi.nlm.nih.gov/pubmed/28753881

227.Porten, S., et al. Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer, 2014. 120: 1794.
https://www.ncbi.nlm.nih.gov/pubmed/24633966

228.Margulis, V., et al. Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma. J Urol, 2020. 203: 690.
https://www.ncbi.nlm.nih.gov/pubmed/31702432

229.Coleman, J.A., et al. Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma. J Clin Oncol, 2023. 41: 1618.
https://www.ncbi.nlm.nih.gov/pubmed/36603175

230.Leow, J.J., et al. Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy. Eur Urol, 2021. 79: 635.
https://www.ncbi.nlm.nih.gov/pubmed/32798146

231.Ali Deb, A., et al. Role of Neoadjuvant Chemotherapy on Pathological, Functional, and Survival Outcomes of Upper Tract Urothelial Carcinoma Patients: A Systematic Review and Meta-Analysis. Urol Res Pract, 2024. 50: 13.
https://www.ncbi.nlm.nih.gov/pubmed/38451126

232.Fletcher, S.A., et al. Oncologic Outcomes in Patients with Residual Upper Tract Urothelial Carcinoma Following Neoadjuvant Chemotherapy. Eur Urol Oncol, 2024. 7: 1061.
https://www.ncbi.nlm.nih.gov/pubmed/38262800

233.Necchi, A., et al. A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02. Urol Oncol, 2022. 40: 10 e1.
https://www.ncbi.nlm.nih.gov/pubmed/34147313

234.Houede, N., et al. Safety and Efficacy of Neoadjuvant Durvalumab Plus Gemcitabine/Cisplatin or Carboplatin in Patients With Operable High-Risk Upper Tract Urothelial Carcinoma: The iNDUCT-GETUG V08 Trial. J Clin Oncol, 2025. 43: 1578.
https://www.ncbi.nlm.nih.gov/pubmed/39951246

235.O’Brien, T., et al. Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial). Eur Urol, 2011. 60: 703.
https://www.ncbi.nlm.nih.gov/pubmed/21684068

236.Ito, A., et al. Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial. J Clin Oncol, 2013. 31: 1422.
https://www.ncbi.nlm.nih.gov/pubmed/23460707

237.Hwang, E.C., et al. Single-dose intravesical chemotherapy after nephroureterectomy for upper tract urothelial carcinoma. Cochrane Database Syst Rev, 2019. 5: CD013160.
https://www.ncbi.nlm.nih.gov/pubmed/31102534

238.Fang, D., et al. Prophylactic intravesical chemotherapy to prevent bladder tumors after nephroureterectomy for primary upper urinary tract urothelial carcinomas: a systematic review and meta-analysis. Urol Int, 2013. 91: 291.
https://www.ncbi.nlm.nih.gov/pubmed/23948770

239.Harraz, A.M., et al. Single Versus Maintenance Intravesical Chemotherapy for the Prevention of Bladder Recurrence after Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Randomized Clinical Trial. Clin Genitourin Cancer, 2019. 17: e1108.
https://www.ncbi.nlm.nih.gov/pubmed/31594736

240.Yamamoto, S., et al. Intravesical irrigation might prevent bladder recurrence in patients undergoing radical nephroureterectomy for upper urinary tract urothelial carcinoma. Int J Urol, 2019. 26: 791.
https://www.ncbi.nlm.nih.gov/pubmed/31081198

241.Freifeld, Y., et al. Intraoperative prophylactic intravesical chemotherapy to reduce bladder recurrence following radical nephroureterectomy. Urol Oncol, 2020. 38: 737 e11.
https://www.ncbi.nlm.nih.gov/pubmed/32641241

242.van Doeveren, T., et al. Intravesical Instillation of Chemotherapy Before Radical Surgery for Upper Urinary Tract Urothelial Carcinoma: The REBACARE Trial. Eur Urol, 2025. 87: 444.
https://www.ncbi.nlm.nih.gov/pubmed/39843302

243.Birtle, A., et al. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Lancet, 2020. 395: 1268.
https://www.ncbi.nlm.nih.gov/pubmed/32145825

244.Birtle, A.J., et al. Improved Disease-Free Survival With Adjuvant Chemotherapy After Nephroureterectomy for Upper Tract Urothelial Cancer: Final Results of the POUT Trial. J Clin Oncol, 2024. 42: 1466.
https://www.ncbi.nlm.nih.gov/pubmed/38350047

245.Xylinas, E., et al. Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy. BJU Int, 2013. 112: 453.
https://www.ncbi.nlm.nih.gov/pubmed/23464979

246.Kaag, M., et al. Preoperative predictors of renal function decline after radical nephroureterectomy for upper tract urothelial carcinoma. BJU Int, 2014. 114: 674.
https://www.ncbi.nlm.nih.gov/pubmed/24314050

247.Kaag, M.G., et al. Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol, 2010. 58: 581.
https://www.ncbi.nlm.nih.gov/pubmed/20619530

248.Tully, K.H., et al. Differences in survival and impact of adjuvant chemotherapy in patients with variant histology of tumors of the renal pelvis. World J Urol, 2020. 38: 2227.
https://www.ncbi.nlm.nih.gov/pubmed/31748954

249.Bajorin, D.F., et al. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N Engl J Med, 2021. 384: 2102.
https://www.ncbi.nlm.nih.gov/pubmed/34077643

250.European Medicines Agency. European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Patients with Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma with Tumor Cell PD-L1 Expression ≥1%. 2022. 2025.
https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf

251.Apolo, A.B., et al. Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma. N Engl J Med, 2025. 392: 45.
https://www.ncbi.nlm.nih.gov/pubmed/39282902

252.Laukhtina, E., et al. Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomes. Crit Rev Oncol Hematol, 2022. 169: 103570.
https://www.ncbi.nlm.nih.gov/pubmed/34902554

253.Hahn, A.W., et al. Effect of Adjuvant Radiotherapy on Survival in Patients with Locoregional Urothelial Malignancies of the Upper Urinary Tract. Anticancer Res, 2016. 36: 4051.
https://www.ncbi.nlm.nih.gov/pubmed/27466512

254.Huang, Y.C., et al. Adjuvant radiotherapy for locally advanced upper tract urothelial carcinoma. Sci Rep, 2016. 6: 38175.
https://www.ncbi.nlm.nih.gov/pubmed/27910890

255.Czito, B., et al. Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter. J Urol, 2004. 172: 1271.
https://www.ncbi.nlm.nih.gov/pubmed/15371822

256.Iwata, T., et al. The role of adjuvant radiotherapy after surgery for upper and lower urinary tract urothelial carcinoma: A systematic review. Urol Oncol, 2019. 37: 659.
https://www.ncbi.nlm.nih.gov/pubmed/31255542

257.Shigeta, K., et al. Does neoadjuvant chemotherapy have therapeutic benefit for node-positive upper tract urothelial carcinoma? Results of a multi-center cohort study. Urol Oncol, 2022. 40: 105 e19.
https://www.ncbi.nlm.nih.gov/pubmed/34454822

258.Tuderti, G., et al. Role of neoadjuvant chemotherapy in patients with locally advanced and clinically positive nodes Upper Tract Urothelial Carcinoma treated with Nephroureterectomy: real-world data from the ROBUUST 2.0 Registry. World J Urol, 2024. 42: 575.
https://www.ncbi.nlm.nih.gov/pubmed/39395052

259.Rai, B.P., et al. Benefit and Harms of Radical Nephroureterectomy as Part of a Multimodal Treatment Strategy for Upper Tract Urothelial Carcinoma Patients Presenting with Clinical Evidence of Regional Lymph Node Metastasis: A Systematic Review and Meta-analysis by the European Association of Urology Guidelines. Eur Urol Oncol, 2025. 8: 841.
https://www.ncbi.nlm.nih.gov/pubmed/39779382

260.Powles, T., et al. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N Engl J Med, 2024. 390: 875.
https://www.ncbi.nlm.nih.gov/pubmed/38446675

261.Moschini, M., et al. Impact of Primary Tumor Location on Survival from the European Organization for the Research and Treatment of Cancer Advanced Urothelial Cancer Studies. J Urol, 2018. 199: 1149.
https://www.ncbi.nlm.nih.gov/pubmed/29158104

262.Gust, K.M., et al. Update on systemic treatment of upper tract urothelial carcinoma: a narrative review of the literature. Transl Androl Urol, 2021. 10: 4051.
https://www.ncbi.nlm.nih.gov/pubmed/34804847

263.Powles, T., et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol, 2021. 22: 931.
https://www.ncbi.nlm.nih.gov/pubmed/34051178

264.Galsky, M.D., et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet, 2020. 395: 1547.
https://www.ncbi.nlm.nih.gov/pubmed/32416780

265.Powles, T., et al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol, 2020. 21: 1574.
https://www.ncbi.nlm.nih.gov/pubmed/32971005

266.van der Heijden, M.S., et al. Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma. N Engl J Med, 2023. 389: 1778.
https://www.ncbi.nlm.nih.gov/pubmed/37870949

267.De Santis, M., et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol, 2012. 30: 191.
https://www.ncbi.nlm.nih.gov/pubmed/22162575

268.Richters, A., et al. Evidence or Prejudice? Critical Re-Analysis of Randomized Controlled Trials Comparing Overall Survival After Cisplatin Versus Carboplatin-Based Regimens in Advanced Urothelial Carcinoma. Clin Genitourin Cancer, 2022. 20: e346.
https://www.ncbi.nlm.nih.gov/pubmed/35039230

269.Powles, T., et al. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N Engl J Med, 2020. 383: 1218.
https://www.ncbi.nlm.nih.gov/pubmed/32945632

270.Powles, T., et al. Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis. Journal of Clinical Oncology, 2020. 38: LBA1.
https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.18_suppl.LBA1

271.Galsky, M.D., et al. Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer. J Clin Oncol, 2020. 38: 1797.
https://www.ncbi.nlm.nih.gov/pubmed/32271672

272.Vuky, J., et al. Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer. J Clin Oncol, 2020. 38: 2658.
https://www.ncbi.nlm.nih.gov/pubmed/32552471

273.Balar, A.V., et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet, 2017. 389: 67.
https://www.ncbi.nlm.nih.gov/pubmed/27939400

274.Bellmunt, J., et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med, 2017. 376: 1015.
https://www.ncbi.nlm.nih.gov/pubmed/28212060

275.Powles, T., et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet, 2018. 391: 748.
https://www.ncbi.nlm.nih.gov/pubmed/29268948

276.Sharma, P., et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol, 2017. 18: 312.
https://www.ncbi.nlm.nih.gov/pubmed/28131785

277.Patel, M.R., et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol, 2018. 19: 51.
https://www.ncbi.nlm.nih.gov/pubmed/29217288

278.Apolo, A.B., et al. Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study. J Clin Oncol, 2017. 35: 2117.
https://www.ncbi.nlm.nih.gov/pubmed/28375787

279.Powles, T., et al. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study. JAMA Oncol, 2017. 3: e172411.
https://www.ncbi.nlm.nih.gov/pubmed/28817753

280.Sharma, P., et al. Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. J Clin Oncol, 2019. 37: 1608.
https://www.ncbi.nlm.nih.gov/pubmed/31100038

281.Rizzo, A., et al. Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 project. Clin Exp Metastasis, 2024. 41: 655.
https://www.ncbi.nlm.nih.gov/pubmed/38850317

282.Siefker-Radtke, A., et al. Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition. Nat Rev Urol, 2018. 15: 112.
https://www.ncbi.nlm.nih.gov/pubmed/29205200

283.Loriot, Y., et al. Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma. N Engl J Med, 2023. 389: 1961.
https://www.ncbi.nlm.nih.gov/pubmed/37870920

284.De Lorenzis, E., et al. Current Knowledge on Genomic Profiling of Upper Tract Urothelial Carcinoma. Genes (Basel), 2021. 12.
https://www.ncbi.nlm.nih.gov/pubmed/33668859

285.Yu, E.Y., et al. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV1397645928201): a multicentre, single-arm, phase 2 trial. Lancet Oncol, 2021. 22: 872.
https://www.ncbi.nlm.nih.gov/pubmed/33991512

286.Powles, T., et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med, 2021. 384: 1125.
https://www.ncbi.nlm.nih.gov/pubmed/33577729

287.Tagawa, S.T., et al. TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors. J Clin Oncol, 2021. 39: 2474.
https://www.ncbi.nlm.nih.gov/pubmed/33929895

288.Drakaki, A., et al. Docetaxel with or without Ramucirumab after Platinum-Based Chemotherapy and Checkpoint Inhibitors in Advanced Urothelial Carcinoma: A Pre-Specified Subgroup Analysis from the Phase 3 RANGE Trial. Bladder Cancer, 2019. 6(1): 43.
https://journals.sagepub.com/doi/10.3233/BLC-190252

289.Seisen, T., et al. Efficacy of Systemic Chemotherapy Plus Radical Nephroureterectomy for Metastatic Upper Tract Urothelial Carcinoma. Eur Urol, 2017. 71: 714.
https://www.ncbi.nlm.nih.gov/pubmed/27912971

290.Moschini, M., et al. Efficacy of Surgery in the Primary Tumor Site for Metastatic Urothelial Cancer: Analysis of an International, Multicenter, Multidisciplinary Database. Eur Urol Oncol, 2020. 3: 94.
https://www.ncbi.nlm.nih.gov/pubmed/31307962

291.Zhang, X., et al. The role of surgery on primary site in metastatic upper urinary tract urothelial carcinoma and a nomogram for predicting the survival of patients with metastatic upper urinary tract urothelial carcinoma. Cancer Med, 2021. 10: 8079.
https://www.ncbi.nlm.nih.gov/pubmed/34647688

292.Dong, F., et al. How do organ-specific metastases affect prognosis and surgical treatment for patients with metastatic upper tract urothelial carcinoma: first evidence from population based data. Clin Exp Metastasis, 2017. 34: 467.
https://www.ncbi.nlm.nih.gov/pubmed/29500709

293.Nazzani, S., et al. Survival Effect of Nephroureterectomy in Metastatic Upper Urinary Tract Urothelial Carcinoma. Clin Genitourin Cancer, 2019. 17: e602.
https://www.ncbi.nlm.nih.gov/pubmed/31005472

294.Morra, S., et al. Survival benefit of nephroureterectomy in systemic therapy exposed metastatic upper tract urinary urothelial carcinoma patients. World J Urol, 2024. 42: 343.
https://www.ncbi.nlm.nih.gov/pubmed/38775841

295.Simsir, A., et al. Prognostic factors for upper urinary tract urothelial carcinomas: stage, grade, and smoking status. Int Urol Nephrol, 2011. 43: 1039.
https://www.ncbi.nlm.nih.gov/pubmed/21547471

296.Siefker-Radtke, A.O., et al. Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. J Urol, 2004. 171: 145.
https://www.ncbi.nlm.nih.gov/pubmed/14665863

297.Abe, T., et al. Impact of multimodal treatment on survival in patients with metastatic urothelial cancer. Eur Urol, 2007. 52: 1106.
https://www.ncbi.nlm.nih.gov/pubmed/17367917

298.Lehmann, J., et al. Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05). Eur Urol, 2009. 55: 1293.
https://www.ncbi.nlm.nih.gov/pubmed/19058907

299.Faltas, B.M., et al. Metastasectomy in older adults with urothelial carcinoma: Population-based analysis of use and outcomes. Urol Oncol, 2018. 36: 9 e11.
https://www.ncbi.nlm.nih.gov/pubmed/28988653

300.Lemke, E., et al. The Role of Metastasectomy in Urothelial Carcinoma: Where Are We in 2020? Clin Genitourin Cancer, 2020. 18: e478.
https://www.ncbi.nlm.nih.gov/pubmed/32085986

301.Oge, O., et al. Proposal for changes in cystoscopic follow-up of patients with low-grade pTa bladder tumor. Eur Urol, 2000. 37: 271.
https://www.ncbi.nlm.nih.gov/pubmed/10720851

302.Holmang, S., et al. Bilateral metachronous ureteral and renal pelvic carcinomas: incidence, clinical presentation, histopathology, treatment and outcome. J Urol, 2006. 175: 69.
https://www.ncbi.nlm.nih.gov/pubmed/16406872

303.Shigeta, K., et al. The Conditional Survival with Time of Intravesical Recurrence of Upper Tract Urothelial Carcinoma. J Urol, 2017. 198: 1278.
https://www.ncbi.nlm.nih.gov/pubmed/28634017

304.Martini, A., et al. Oncologic Surveillance After Radical Nephroureterectomy for High-risk Upper Tract Urothelial Carcinoma. Eur Urol Oncol, 2022. 5: 451.
https://www.ncbi.nlm.nih.gov/pubmed/35504834

305.Katims, A.B., et al. Predictors and Patterns of Nonurothelial Recurrence After Nephroureterectomy for Upper Tract Urothelial Carcinoma (UCAN Collaboration). J Urol, 2025. 214: 407.
https://www.ncbi.nlm.nih.gov/pubmed/40526449

306.Holmang, S., et al. Long-term follow-up of patients with tumours of the renal pelvis and ureter: how often is a bladder tumour diagnosed after five tumour-free years? Scand J Urol, 2014. 48: 65.
https://www.ncbi.nlm.nih.gov/pubmed/23883372

307.Basile, G., et al. Oncologic surveillance intensity after endoscopic treatment of upper tract urothelial carcinoma. Minerva Urol Nephrol, 2024. 76: 88.
https://www.ncbi.nlm.nih.gov/pubmed/38426423

308.Mandalapu, R.S., et al. Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of low-risk upper tract urothelial carcinoma. World J Urol, 2017. 35: 355.
https://www.ncbi.nlm.nih.gov/pubmed/27233780

309.Bagley, D.H., et al. Ureteroscopic laser treatment of upper urinary tract neoplasms. World J Urol, 2010. 28: 143.
https://www.ncbi.nlm.nih.gov/pubmed/20229233

310.Mohapatra, A., et al. Importance of long-term follow-up after endoscopic management for upper tract urothelial carcinoma and factors leading to surgical management. Int Urol Nephrol, 2020. 52: 1465.
https://www.ncbi.nlm.nih.gov/pubmed/32157621

311.Xylinas, E., et al. Multifocal carcinoma in situ of the upper tract is associated with high risk of bladder cancer recurrence. Eur Urol, 2012. 61: 1069.
https://www.ncbi.nlm.nih.gov/pubmed/22402109

312.Zhang, M.L., et al. A review of upper urinary tract cytology performance before and after the implementation of The Paris System. Cancer Cytopathol, 2021. 129: 264.
https://www.ncbi.nlm.nih.gov/pubmed/32897658

313.Chouhan, H., et al. Evaluation of Urinalysis-Based Screening for Urothelial Carcinoma in Patients With Lynch Syndrome. Dis Colon Rectum, 2022. 65: 40.
https://www.ncbi.nlm.nih.gov/pubmed/34882627

314.Myrhoj, T., et al. Screening for urinary tract cancer with urine cytology in Lynch syndrome and familial colorectal cancer. Fam Cancer, 2008. 7: 303.
https://www.ncbi.nlm.nih.gov/pubmed/18389386

315.Therkildsen, C., et al. Molecular subtype classification of urothelial carcinoma in Lynch syndrome. Mol Oncol, 2018. 12: 1286.
https://www.ncbi.nlm.nih.gov/pubmed/29791078

316.Mariappan, P. Propensity for Quality: No Longer a Tenuous Proposition in Bladder Cancer. Eur Urol, 2020. 78: 60.
https://www.ncbi.nlm.nih.gov/pubmed/32444262

317.Konig, F., et al. Quality indicators for the management of high-risk upper tract urothelial carcinoma requiring radical nephroureterectomy. Curr Opin Urol, 2021. 31: 291.
https://www.ncbi.nlm.nih.gov/pubmed/33973537

318.Konig, F., et al. Pentafecta for Radical Nephroureterectomy in Patients with High-Risk Upper Tract Urothelial Carcinoma: A Proposal for Standardization of Quality Care Metrics. Cancers (Basel), 2022. 14(7): 1781.
https://www.ncbi.nlm.nih.gov/pubmed/35406553

319.Soria, F., et al. Radical Nephroureterectomy Tetrafecta: A Proposal Reporting Surgical Strategy Quality at Surgery. Eur Urol Open Sci, 2022. 42: 1.
https://www.ncbi.nlm.nih.gov/pubmed/35911084

320.Sui, W., et al. The Impact of Hospital Volume on Short-term and Long-term Outcomes for Patients Undergoing Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. Urology, 2021. 147: 135.
https://www.ncbi.nlm.nih.gov/pubmed/32891638

Not found